For years patients have said the generic Wellbutrin doesn’t work as well as brand name. The FDA finally took action against manufactures of the generics, admitting Clinical Trials were not performed on 300 mg Extended Release tablets. Follow up test found discrepancies in Bioeqivalence. The FDA holds responsibility as well, they are accountable to the public. The FDA requires all companies who manufacture medication to prove medication is safe, effective…equivalent or not for generics. This process can take years. The over looked, the lack of testing on higher mg caused many patients to take ineffective medicine suffering higher levels of depression.
Update: Bupropion Hydrochloride Extended-Release 300 mg Bioequivalence Studies
FDA has approved five generic versions of Wellbutrin XL 300 mg. Each of these generics was approved based on bioequivalence studies comparing the 150 mg strength of the products to Wellbutrin XL 150 mg. Studies were not performed directly on the 300…
View original post 154 more words